Insider Selling: Medtronic (NYSE:MDT) EVP Sells $1,000,320.00 in Stock

Key Points

• Medtronic EVP Michael Marinaro sold 10,420 shares for approximately $1.0 million at $96 per share under a pre-arranged Rule 10b5-1 trading plan, reducing his stake by 8.96% to 105,916 shares.
• Medtronic shares fell 0.7% to $94.79, while the company reported quarterly EPS and revenue above analyst expectations, with revenue up 13.7% year over year.
• The company maintains a $0.72 quarterly dividend, equivalent to a 3.0% yield, and analysts hold a “Moderate Buy” consensus rating with an average price target of $102.88.

Medtronic PLC (NYSE:MDT - Get Free Report) EVP Michael Marinaro sold 10,420 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the transaction, the executive vice president owned 105,916 shares of the company's stock, valued at $10,167,936. This trade represents a 8.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medtronic Trading Down 0.7%

Shares of NYSE MDT traded down $0.66 during midday trading on Friday, hitting $94.79. The company's stock had a trading volume of 30,274,266 shares, compared to its average volume of 11,408,682. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The business's 50 day moving average is $90.87 and its two-hundred day moving average is $84.95. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The firm has a market cap of $121.25 billion, a P/E ratio of 23.35, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period last year, the company earned $1.26 EPS. Medtronic's quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.98 EPS for the current year.

Medtronic Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic's payout ratio is currently 70.94%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on MDT. Needham & Company LLC reaffirmed a "buy" rating on shares of Medtronic in a research report on Thursday, September 17th. Truist Financial reissued a "hold" rating and set a $99.00 price target (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Royal Bank Of Canada restated an "outperform" rating and set a $118.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Bank of America raised their price target on Medtronic from $95.00 to $110.00 and gave the company a "buy" rating in a research note on Wednesday, September 2nd. Finally, Robert W. Baird lifted their price objective on Medtronic from $91.00 to $100.00 and gave the company a "neutral" rating in a report on Wednesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Medtronic has an average rating of "Moderate Buy" and an average price target of $102.88.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
• Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
• Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
• Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
• Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

Institutional Trading of Medtronic

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Medtronic by 0.7% during the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company's stock worth $8,919,846,000 after acquiring an additional 838,220 shares in the last quarter. State Street Corp grew its holdings in Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company's stock worth $5,005,320,000 after purchasing an additional 1,658,301 shares during the last quarter. Bank of America Corp DE grew its holdings in Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company's stock worth $2,254,200,000 after purchasing an additional 1,343,220 shares during the last quarter. First Eagle Investment Management LLC increased its position in shares of Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company's stock worth $1,078,321,000 after purchasing an additional 3,739,288 shares in the last quarter. Finally, WCM Investment Management LLC acquired a new position in shares of Medtronic during the first quarter worth $965,922,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.